← Back to Clinical Trials
Recruiting NCT06542705

NCT06542705 Effect of Internal Brace on Outcomes Following ACL Reconstruction With BTB Autograft

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06542705
Status Recruiting
Phase
Sponsor NYU Langone Health
Condition ACL Reconstruction
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2025-03-17
Primary Completion 2029-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 35 Years
Study Type INTERVENTIONAL
Interventions
Arthrex Internal BraceACL Reconstruction

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 90 participants in total. It began in 2025-03-17 with a primary completion date of 2029-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to assess Anterior Cruciate Ligament (ACL) healing through analyzing clinical, radiographic, functional and patient-reported outcomes following ACL reconstruction with bone-tendon-bone autograft with and without internal bracing.

Eligibility Criteria

Inclusion Criteria: * Patients undergoing ACLR with BTB autograft * Patients ages 18-35, inclusive * Ability to undergo standard rehab protocol and full, painless range of motion at the time of surgery of their operative knee Exclusion Criteria: * Osteoarthritis defined by Kellgren-Lawrence grade 2 or higher on preoperative weightbearing radiographs * Significant chondral injury as defined by grade 3-4 lesion greater than 2cm2 * History of autoimmune or inflammatory disease * Prior ipsilateral knee ligament surgery or multi-ligament knee injury * Concomitant Lateral extra-articular tenodesis (LET) procedure * History of contralateral ACL surgery * Younger than 18 years of age * Older than 35 years of age

Contact & Investigator

Central Contact

Sangmin Lee

✉ sangmin.lee3@nyulangone.org

📞 201-835-9117

Principal Investigator

Michael J. Alaia, MD

PRINCIPAL INVESTIGATOR

NYU Langone Health

Frequently Asked Questions

Who can join the NCT06542705 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 35 Years, studying ACL Reconstruction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06542705 currently recruiting?

Yes, NCT06542705 is actively recruiting participants. Contact the research team at sangmin.lee3@nyulangone.org for enrollment information.

Where is the NCT06542705 trial being conducted?

This trial is being conducted at New York, United States.

Who is sponsoring the NCT06542705 clinical trial?

NCT06542705 is sponsored by NYU Langone Health. The principal investigator is Michael J. Alaia, MD at NYU Langone Health. The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology